KOD: Kodiak Sciences, Inc.
About
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
Current Value
$5.651 Year Return
Current Value
$5.651 Year Return
Key Details
Market Cap
$296.80M
P/E Ratio
-1.55
1Y Stock Return
150.67%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
1.6
Strategies that include KOD
Stock's related to KOD
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CRSP | 44.08% | $4.01B | -30.49% | 0.00% |
| FARO | 44.07% | $486.17M | +40.51% | 0.00% |
| ACLX | 43.23% | $4.74B | +69.19% | 0.00% |
| RXRX | 42.69% | $1.80B | -4.13% | 0.00% |
| KMPR | 40.88% | $4.52B | +69.87% | 1.75% |
| LMND | 39.41% | $2.87B | +150.56% | 0.00% |
| INMD | 38.91% | $1.50B | -21.29% | 0.00% |
| RCEL | 38.89% | $321.96M | +27.43% | 0.00% |
| RCKT | 38.74% | $1.20B | -39.83% | 0.00% |
| FUBO | 38.43% | $474.41M | -54.49% | 0.00% |
| INFA | 38.22% | $7.86B | +5.06% | 0.00% |
| KYMR | 37.79% | $2.77B | +125.95% | 0.00% |
| MGTX | 37.18% | $467.36M | +9.12% | 0.00% |
| MVIS | 36.99% | $198.19M | -60.14% | 0.00% |
| PGEN | 36.66% | $228.91M | -28.00% | 0.00% |
| BOC | 36.44% | $456.18M | -1.56% | 0.00% |
| CLSK | 36.31% | $3.65B | +211.70% | 0.00% |
| DDD | 36.30% | $402.06M | -35.13% | 0.00% |
| XNCR | 36.20% | $1.65B | +27.73% | 0.00% |
| MNKD | 36.03% | $1.89B | +84.91% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| IMNN | 0.02% | $10.02M | -22.89% | 0.00% |
| NNVC | 0.06% | $19.66M | +25.69% | 0.00% |
| X | -0.16% | $8.76B | +13.32% | 0.51% |
| CNA | -0.19% | $13.16B | +23.03% | 3.61% |
| TCTM | -0.29% | $8.10M | -42.99% | 0.00% |
| TK | -0.30% | $728.26M | +11.06% | 0.00% |
| FTNT | -0.33% | $69.59B | +72.67% | 0.00% |
| KSPI | 0.40% | $20.86B | +18.06% | 3.37% |
| BTSG | -0.42% | $3.25B | +43.46% | 0.00% |
| AXS | -0.48% | $7.14B | +55.12% | 2.06% |
| TMUS | 0.50% | $270.63B | +56.92% | 0.83% |
| LMT | 0.51% | $126.40B | +18.99% | 2.36% |
| MNR | -0.72% | $1.66B | -10.71% | 15.90% |
| CAH | -0.72% | $28.64B | +12.14% | 1.70% |
| KNDI | -0.77% | $96.53M | -60.11% | 0.00% |
| UNH | -0.83% | $531.00B | +6.93% | 1.37% |
| UNM | 0.85% | $13.16B | +69.20% | 2.16% |
| ADBE | -0.95% | $219.93B | -18.23% | 0.00% |
| MA | 0.96% | $476.78B | +27.02% | 0.51% |
| HIHO | -0.97% | $8.63M | 0.00% | 6.12% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| RNR | -17.07% | $13.74B | +23.09% | 0.58% |
| ACGL | -16.75% | $36.00B | +16.84% | 0.00% |
| MCK | -15.56% | $78.15B | +35.51% | 0.42% |
| MKL | -15.48% | $21.48B | +16.38% | 0.00% |
| CME | -14.69% | $82.76B | +9.21% | 1.98% |
| LITB | -12.80% | $35.48M | -75.45% | 0.00% |
| PGR | -12.65% | $149.10B | +57.29% | 0.45% |
| EG | -12.63% | $15.92B | -8.98% | 2.02% |
| MMC | -11.32% | $108.41B | +10.89% | 1.37% |
| REX | -10.78% | $772.08M | +19.14% | 0.00% |
| CBOE | -10.51% | $21.46B | +15.84% | 1.11% |
| RELY | -9.69% | $3.96B | -7.42% | 0.00% |
| CI | -9.53% | $89.70B | +12.57% | 1.68% |
| PRPO | -9.37% | $9.10M | -13.65% | 0.00% |
| HUM | -9.31% | $33.45B | -45.22% | 1.25% |
| NLOP | -8.01% | $458.04M | +94.60% | 0.00% |
| STG | -7.99% | $35.67M | +7.92% | 0.00% |
| OXBR | -7.50% | $19.05M | +178.18% | 0.00% |
| VIRT | -7.32% | $3.17B | +110.38% | 2.60% |
| MNOV | -6.24% | $93.19M | +2.15% | 0.00% |
ETF's related to KOD
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 48.41% | $6.58B | 0.35% |
| ARKG | 48.24% | $1.13B | 0.75% |
| IWC | 47.39% | $933.99M | 0.6% |
| GNOM | 47.23% | $70.59M | 0.5% |
| KOMP | 45.58% | $2.09B | 0.2% |
| IWO | 44.98% | $12.56B | 0.24% |
| IWM | 44.68% | $75.73B | 0.19% |
| VTWO | 44.54% | $12.38B | 0.1% |
| PBE | 44.38% | $258.53M | 0.58% |
| NUSC | 43.93% | $1.27B | 0.31% |
| XPH | 43.89% | $157.87M | 0.35% |
| ISCG | 43.87% | $640.00M | 0.06% |
| IBB | 43.85% | $6.66B | 0.45% |
| IBHF | 43.58% | $582.74M | 0.35% |
| ESML | 43.54% | $1.90B | 0.17% |
| EZM | 43.39% | $823.84M | 0.38% |
| BSVO | 43.20% | $1.53B | 0.47% |
| VBK | 43.10% | $19.31B | 0.07% |
| XSHD | 43.04% | $54.49M | 0.3% |
| SMOT | 43.01% | $374.04M | 0.49% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| CANE | 0.26% | $17.72M | 0.29% |
| FLRN | -0.79% | $2.33B | 0.15% |
| KRBN | 1.08% | $242.47M | 0.85% |
| CSHI | -1.11% | $482.85M | 0.38% |
| HDRO | 1.22% | $164.26M | 0.3% |
| HIGH | 1.55% | $302.78M | 0.51% |
| WEAT | 1.88% | $120.27M | 0.28% |
| DBB | 2.02% | $126.37M | 0.77% |
| TPMN | 2.31% | $40.60M | 0.65% |
| UNG | -2.51% | $908.80M | 1.06% |
| DBA | -2.68% | $755.88M | 0.93% |
| USCI | 2.77% | $185.47M | 1.07% |
| DUSB | 3.05% | $797.63M | 0.15% |
| MINT | -3.44% | $11.62B | 0.35% |
| FTGC | 4.14% | $2.17B | 1.02% |
| GBIL | -4.48% | $5.60B | 0.12% |
| BSCO | 4.77% | $2.35B | 0.1% |
| CLOI | 4.83% | $715.40M | 0.4% |
| SEIX | 4.90% | $268.81M | 0.62% |
| COMT | 5.25% | $829.06M | 0.48% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -36.61% | $388.04M | 1.43% |
| VIXY | -23.95% | $195.31M | 0.85% |
| USDU | -17.95% | $201.97M | 0.5% |
| UUP | -14.44% | $309.25M | 0.77% |
| CTA | -11.04% | $350.27M | 0.78% |
| TAIL | -10.20% | $67.98M | 0.59% |
| AGZD | -10.14% | $142.76M | 0.23% |
| KCCA | -9.20% | $220.51M | 0.87% |
| KMLM | -8.16% | $353.87M | 0.9% |
| CORN | -7.93% | $61.12M | 0.2% |
| EQLS | -7.58% | $76.08M | 1% |
| SOYB | -7.22% | $27.32M | 0.22% |
| JBBB | -6.27% | $1.26B | 0.49% |
| DBMF | -5.49% | $1.02B | 0.85% |
| GBIL | -4.48% | $5.60B | 0.12% |
| MINT | -3.44% | $11.62B | 0.35% |
| DBA | -2.68% | $755.88M | 0.93% |
| UNG | -2.51% | $908.80M | 1.06% |
| CSHI | -1.11% | $482.85M | 0.38% |
| FLRN | -0.79% | $2.33B | 0.15% |
News
Yahoo
KOD reports a narrower-than-expected loss for the third quarter of 2024. The company provides updates regarding its pipeline development plans.
SeekingAlpha
Kodiak's stock surged 160% since September 2023, despite initial setbacks with tarcocimab in diabetic macular edema studies. Check out my analysis of KOD.
Yahoo
Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2024.
Finnhub
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results Palo Alto, CA - November 14, 2024 - Kodiak Sciences Inc. , today reported business...
Yahoo
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences. Members of the management team will also be available for one-on-one meetings.
Yahoo
Major U.S. stock indices have recently slipped from record highs as investors brace for a wave of earnings reports, highlighting the market's ongoing volatility and uncertainty. Despite these fluctuations, penny stocks continue to present intriguing opportunities for investors looking to explore potential growth in smaller or newer companies. While the term "penny stock" might seem outdated, these investments can still offer significant upside when backed by strong financials and sound...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.